IRLAB Therapeutics AB Class A (DE:6IRA)
FRANKFURT:6IRA
Want to see DE:6IRA full AI Analyst Report?
6IRA Stock Chart & Stats
€0.18
-€0.01(-1.25%)
At close: 4:00 PM EST
€0.18
-€0.01(-1.25%)
Day’s Range― - ―
52-Week Range€0.12 - €0.68
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€11.04M
Enterprise Value€68.59M
Total Cash (Recent Filing)€81.86M
Total Debt (Recent Filing)€29.95M
Price to Earnings (P/E)―
Beta<0.01
Next Earnings
May 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding84,858,246
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.48
Price to Book (P/B)4.30
Price to Sales (P/S)2.30
P/FCF Ratio-2.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.25
Revenue Forecast (FY)€10.19M
Bulls Say, Bears Say
Bulls Say
CNS-focused R&DA concentrated R&D focus on CNS disorders, especially Parkinson’s, creates durable domain expertise and regulatory familiarity. This specialization supports higher barriers to entry, clearer clinical pathways and partner interest, improving the likelihood of long-term value capture if candidates advance.
Partnership-driven Revenue ModelA business-development revenue model centered on upfronts, milestones and royalties enables non-dilutive funding and external validation. Strategic licensing and collaborations can finance clinical programs, de-risk development stages and provide milestone cash flows that sustain operations over multi-year programs.
Improving Cash Burn TrendReported reduction in cash burn in 2024–2025 signals improving expense discipline or better funding cadence. Sustained improvement in operating/free cash flow deficits extends runway and lowers near-term financing pressure, increasing odds of advancing clinical milestones without immediate dilution.
Bears Say
Persistent Multi-year LossesMulti-year, deep losses indicate that R&D and other costs far outstrip revenues. Persistent negative profitability erodes retained earnings, limits reinvestment capacity, and forces continued reliance on external capital or partnerships, raising execution and financing risk over the medium term.
Consistent Negative Cash FlowNegative operating and free cash flow across multiple years means the business cannot self-fund development. Ongoing cash burn increases dependency on financing or partner payments, which can constrain strategic choices, dilute shareholders or delay programs if capital access tightens.
Equity Erosion And Falling AssetsSubstantial equity decline and falling assets weaken the balance sheet cushion. Even with moderate current leverage, diminished equity reduces borrowing headroom and shock absorption capacity, increasing vulnerability to further losses and limiting flexibility for opportunistic investment or partnerships.
IRLAB Therapeutics AB Class A News
6IRA FAQ
What was IRLAB Therapeutics AB Class A’s price range in the past 12 months?
IRLAB Therapeutics AB Class A lowest stock price was €0.12 and its highest was €0.68 in the past 12 months.
What is IRLAB Therapeutics AB Class A’s market cap?
IRLAB Therapeutics AB Class A’s market cap is €11.04M.
When is IRLAB Therapeutics AB Class A’s upcoming earnings report date?
IRLAB Therapeutics AB Class A’s upcoming earnings report date is May 06, 2026 which is in 5 days.
How were IRLAB Therapeutics AB Class A’s earnings last quarter?
IRLAB Therapeutics AB Class A released its earnings results on Feb 25, 2026. The company reported -€0.026 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.026.
Is IRLAB Therapeutics AB Class A overvalued?
According to Wall Street analysts IRLAB Therapeutics AB Class A’s price is currently Overvalued.
Does IRLAB Therapeutics AB Class A pay dividends?
IRLAB Therapeutics AB Class A does not currently pay dividends.
What is IRLAB Therapeutics AB Class A’s EPS estimate?
IRLAB Therapeutics AB Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does IRLAB Therapeutics AB Class A have?
IRLAB Therapeutics AB Class A has 84,858,246 shares outstanding.
What happened to IRLAB Therapeutics AB Class A’s price movement after its last earnings report?
IRLAB Therapeutics AB Class A reported an EPS of -€0.026 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.051%.
Which hedge fund is a major shareholder of IRLAB Therapeutics AB Class A?
Currently, no hedge funds are holding shares in DE:6IRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
IRLAB Therapeutics AB Class A
IRLAB Therapeutics AB (publ) develops drugs for the treatment of Parkinson's disease. The company develops Mesdopetam that is in phase IIb/III clinical studies for the treatment of dyskinesia; and Pirepemat, which is in phase IIb clinical trial for the treatment of Postural dysfunction. Its preclinical stage products include IRL942 and 1009 research programs for the treatment of neurodegenerative disorders and ageing; and IRL757 to treat apathy in neurological diseases. In addition, the company develops P003, a research project that develops drugs for the treatment of newly diagnosed Parkinson's disease. IRLAB Therapeutics AB (publ) was incorporated in 2013 and is based in Gothenburg, Sweden.
Technical Analysis
Isofol Medical AB
―
Xintela AB
―
Elicera Therapeutics AB
―
Active Biotech AB
―
Initiator Pharma A/S
―